Trial reportDrug metabolism and disposition: the biological fate of chemicals2019
Continuum of Host-Gut Microbial Co-metabolism: Host CYP3A4/3A7 are Responsible for Tertiary Oxidations of Deoxycholate Species.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Drug metabolism and disposition: the biological fate of chemicals, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Exploring the Fecal Metabolome in Infants With Cow's Milk Allergy: The Distinct Impacts of Cow's Milk Protein Tolerance Acquisition and of Synbiotic Supplementation.Molecular nutrition & food research · 2025Trial
- Effect of a Flaxseed Lignan Intervention on Circulating Bile Acids in a Placebo-Controlled Randomized, Crossover Trial.Nutrients · 2020Trial
- Untargeted Metabolomics Reveal New Endogenous Plasma Biomarkers Associated with CYP3A Inhibition in Humans.Clinical pharmacology and therapeutics · 2026Article
- Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.Hepatology (Baltimore, Md.) · 2025Review
- 1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of drug-drug interaction with moderate CYP3A inhibitor.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Microbiome metabolite quantification methods enabling insights into human health and disease.Methods (San Diego, Calif.) · 2024Review
- Review
- High-fat diets enhance and delay ursodeoxycholic acid absorption but elevate circulating hydrophobic bile salts.Frontiers in pharmacology · 2023Article
- The Role of CYP3A in Health and Disease.Biomedicines · 2022Review
- Plasma metabolomic profiling reveals factors associated with dose-adjusted trough concentration of tacrolimus in liver transplant recipients.Frontiers in pharmacology · 2022Article
- Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug-Drug Interaction in Healthy Volunteers.Journal of personalized medicine · 2021Article
- Compensatory Transition of Bile Acid Metabolism from Fecal Disposition of Secondary Bile Acids to Urinary Excretion of Primary Bile Acids Underlies Rifampicin-Induced Cholestasis in Beagle Dogs.ACS pharmacology & translational science · 2021Article
- The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?Journal of personalized medicine · 2021Article
- Species Differences of Bile Acid Redox Metabolism: Tertiary Oxidation of Deoxycholate is Conserved in Preclinical Animals.Drug metabolism and disposition: the biological fate of chemicals · 2020Article
- Stereoselective Oxidation Kinetics of Deoxycholate in Recombinant and Microsomal CYP3A Enzymes: Deoxycholate 19-Hydroxylation Is an In Vitro Marker of CYP3A7 Activity.Drug metabolism and disposition: the biological fate of chemicals · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 2 countries.
Jian ZhangKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Ling-Zhi GaoKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Yu-Jie ChenKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Ping-Ping ZhuKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Shan-Shan YinKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Ming-Ming SuKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Yan NiKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Jia MiaoKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Wen-Lin WuKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Hong ChenKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Kim L R BrouwerKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Chang-Xiao LiuKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Liang XuKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.).
Wei JiaKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.) lanwoco@scu.edu.cn wjia@cc.hawaii.edu.
Ke LanKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, China (J.Z., L.Z.G., Y.J.C., P.P.Z., S.S.Y., L.X., K.L.); Metabolomics Shared Resource, University of Hawaii Cancer Center, Honolulu, Hawaii (M.M.S., Y.N., W.J.); Institute of Clinical Pharmacology, West China Hospital, Sichuan University, Chengdu, China (J.M.); Chengdu Institutes for Food and Drug Control, Chengdu, China (W.L.W., H.C.); UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina (K.L.R.B.); State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, China (C.X.L.); and Chengdu Health-Balance Medical Technology Co., Ltd., Chengdu, China (S.S.Y.) lanwoco@scu.edu.cn wjia@cc.hawaii.edu.
Tianjin Institute of Pharmaceutical Research (China) · CNUniversity of Hawaii Cancer CenterUniversity of North Carolina at Chapel Hill · USSichuan University · CNUniversity of Hawaii System · USChengdu Medical College · CNUniversity of Hawaiʻi at Mānoa · US
Funding
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2MALTERED HEPATIC DISPOSITION OF ANIONIC DRUGS-MECHANISMSR01GM041935 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BROUWER, KIM L.R. · 1997 to 2016
$6.5MMechanisms of Altered Hepatic Transport: Impact on Drug TherapyR35GM122576 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER · 2017 to 2026
$5.7MALTERED HEPATIC DISPOSITION OF ANIONIC DRUGS-MECHANISMSR56GM041935 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BROUWER, KIM L.R. · 2009 to 2009
$365kNCI NIH HHS P30 CA071789NIGMS NIH HHS R01 GM041935NIGMS NIH HHS R35 GM122576NIGMS NIH HHS R56 GM041935
Abstract
The gut microbiota modifies endogenous primary bile acids (BAs) to produce exogenous secondary BAs, which may be further metabolized by cytochrome P450 enzymes (P450s). Our primary aim was to examine how the host adapts to the stress of microbe-derived secondary BAs by P450-mediated oxidative modifications on the steroid nucleus. Five unconjugated tri-hydroxyl BAs that were structurally and/or biologically associated with deoxycholate (DCA) were determined in human biologic samples by liquid chromatography-tandem mass spectrometry in combination with enzyme-digestion techniques. They were identified as DCA-19-ol, DCA-6
Indexed as
AdultCytochrome P-450 CYP3ADeoxycholic AcidFemaleGastrointestinal MicrobiomeHealthy VolunteersHumansHydroxylationLiverMaleMicrosomes, LiverOxidation-ReductionYoung AdultCYP3A4 protein, humanCYP3A7 protein, humanCytochrome P-450 CYP3ADeoxycholic Acid
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.